Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
My Bing
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA approves new Alzheimer's treatment, donanemab from Eli Lilly
Branded as Kisunla by drugmaker Eli Lilly, donanemab's approval follows years of setbacks and delays in getting the experimental Alzheimer's treatment to market, despite promising clinical trial results. Eli Lilly says the drug will be available within weeks following the approval.
UNLV researcher optimistic as Alzheimer’s drug donanemab receives FDA approval
For Dr. Jeffrey Cummings, a brain health researcher and professor at UNLV, this is an exciting time in the fight against Alzheimer’s disease. Federal health advisers in May voted to
FDA approves Alzheimer’s drug donanemab after months of delay
The Food and Drug Administration granted approval Tuesday to a closely watched Alzheimer’s drug, concluding that the benefits of modestly slowing the progression of the devastating disease outweigh its risks,
FDA approves Eli Lilly’s Kisunla (donanemab) for early AD
GlobalData forecasts that Leqembi and Kisunla could generate global sales of approximately $3.5 billion and $2.0 billion respectively by 2030.
FDA approves new drug for Alzheimer’s disease: ‘Meaningful results’
The FDA has approved a new medication for people with Alzheimer’s disease. Eli Lilly’s Kisunla (donanemab) is a once-monthly injection intended for adults with early symptomatic Alzheimer's disease.
FDA approves donanemab, Eli Lilly’s treatment for early Alzheimer’s disease
The US Food and Drug Administration on Tuesday approved donanemab, a monoclonal antibody designed to slow the progression of early symptomatic Alzheimer’s disease.
FDA Approves Eli Lilly’s Alzheimer’s Drug Donanemab
Eli Lilly’s donanemab—to be sold under the brand name Kisunla—received regulatory approval as a monthly injection after an 18-month trial showed “very meaningful results” in slowing cognitive and functional decline in patients with Alzheimer’s, the company said.
FDA approves Donanemab, new Eli Lilly treatment for early Alzheimer’s disease
A new treatment that could slow Alzheimer’s disease has been approved by the Food and Drug Administration. The drug Donanemab will be marketed under the brand name Kisunla.
FDA approves 'donanemab' treatment for Alzheimer's disease
The drug contains an antibody that aims to slow the progression of the incurable Alzheimer’s disease. It operates by eliminating the buildup of amyloid protein plaque in the brain.
1d
on MSN
FDA approves 'Donanemab' to treat Alzheimer's Disease
The Food and Drug Administration recently approved a new drug called '
Donanemab
' to treat the debilitating Alzheimer's ...
technologynetworks
3d
New Alzheimer’s Drug Donanemab Approved by FDA
The drug donanemab (also known as Kisunla™) has been approved by the US Food and Drug Administration (FDA) for the treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Blames 'internet culture'
Tests positive for COVID
Missing cruise teen found
Judge declines to dismiss suit
Alaska may ban cruise ships
Mob ransacks CA mini-mart
Actress Belushi-Pisano dies
Loses deals following arrest
Pays tribute to Jon Landau
Boat capsizes on Lake Erie
Frozen garbage on Everest
Texas book ban review
Body found in sleeping bag
Beryl to hit TX as hurricane
Speaks at Essence Festival
2 boys shot at NYC McD's
Job scams surge in 2023
Mars mission wraps up
'Cross' sets premiere date
NBA free agency 2024
Criticizes US-China chip war
PA Capitol bomb threat
11 killed in Nepal landslides
'Moana' in the works
Lake fire grows: 12K acres
Hamas awaits ISR response
Beats Artem Harutyunyan
Rookie's historic game
NBA Summer League debut
Campaigns in Pennsylvania
Pitt's 'F1' film drops teaser
Deputies injured in crash
Nate Diaz beats Masvidal
3 injured in Hezbollah attack
MS escaped inmates caught
Blaze injures 15 firefighters
Related topics
Eli Lilly
FDA
Alzheimer's disease
Food and Drug Administration
Kisunla
Feedback